Cargando…

Structure and dynamics of the EGFR/HER2 heterodimer

HER2 belongs to the human epidermal growth factor receptor tyrosine kinase family. Its overexpression or hyperactivation is a leading cause for multiple types of cancers. HER2 functions mainly through dimerization with other family members, such as EGFR. However, the molecular details for heterodime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Xue, Sun, Pengyu, Wang, Xinghao, Long, Changkun, Liao, Shuyun, Dang, Song, Zhuang, Shangshang, Du, Yongtao, Zhang, Xinyi, Li, Nan, He, Kangmin, Zhang, Zhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925823/ https://www.ncbi.nlm.nih.gov/pubmed/36781849 http://dx.doi.org/10.1038/s41421-023-00523-5

Ejemplares similares

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Peckys, Diana B., et al.
Publicado: (2021)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
por: Choi, Byoungsan, et al.
Publicado: (2020)

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
por: Shin, Jung Won, et al.
Publicado: (2019)

HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial
por: Barber, Paul R, et al.
Publicado: (2019)

Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
por: Zhao, Jun, et al.
Publicado: (2021)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Equimolar heterodimers in microtubules
Publicado: (1982)

Heterodimers reign in the embryo
por: Tajer, Benjamin, et al.
Publicado: (2017)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

The Salmonella Typhimurium Effector SpvB Subverts Host Membrane Trafficking by Targeting Clathrin and AP-1
por: Yuan, Yi, et al.
Publicado: (2023)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Aptameric Probe Specifically Binding Protein Heterodimer Rather Than Monomers
por: Bing, Tao, et al.
Publicado: (2019)

A new obligate CXCL4–CXCL12 heterodimer for studying chemokine heterodimer activities and mechanisms
por: Nguyen, Khanh T.P., et al.
Publicado: (2022)

SAT009 Investigating The Role Of Hepatic Small Heterodimer Partner In Regulating Gallstone Formation
por: Dang, Nathanlown Mun, et al.
Publicado: (2023)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

The marriage of chemokines and galectins as functional heterodimers
por: von Hundelshausen, Philipp, et al.
Publicado: (2021)

Modeling the Heterodimer Interfaces of Melatonin Receptors
por: Tse, Lap Hang, et al.
Publicado: (2021)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Small Heterodimer Partner Regulates Circadian Cytochromes p450 and Drug-Induced Hepatotoxicity
por: Zhang, Tianpeng, et al.
Publicado: (2018)

Structural basis of tubulin detyrosination by VASH2/SVBP heterodimer
por: Zhou, Chen, et al.
Publicado: (2019)

Protein subunit interfaces: heterodimers versus homodimers
por: Zhanhua, Cui, et al.
Publicado: (2005)

Functional Cis-Heterodimers of N- and R-Cadherins
por: Shan, Wei-Song, et al.
Publicado: (2000)

Two-pore Channels Form Homo- and Heterodimers
por: Rietdorf, Katja, et al.
Publicado: (2011)

Small Heterodimer Partner and Innate Immune Regulation
por: Yuk, Jae-Min, et al.
Publicado: (2016)

Chemokines and galectins form heterodimers to modulate inflammation
por: Eckardt, Veit, et al.
Publicado: (2020)

Π-Stacking in Heterodimers of Propargylbenzene with (Fluoro)phenylacetylenes
por: Kundu, Aniket, et al.
Publicado: (2021)

Heterodimers Are an Integral Component of Chemokine Signaling Repertoire
por: Kaffashi, Kimia, et al.
Publicado: (2023)

MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer
por: Zhang, Mingliang, et al.
Publicado: (2021)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Nuclear Receptor Small Heterodimer Partner in Apoptosis Signaling and Liver Cancer
por: Zhang, Yuxia, et al.
Publicado: (2011)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022)

Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
por: Xue, Lu, et al.
Publicado: (2018)

Atomistic molecular dynamics simulations of tubulin heterodimers explain the motion of a microtubule
por: Nasedkin, Alexandr, et al.
Publicado: (2021)

Evolutionary Couplings and Molecular Dynamic Simulations Highlight Details of GPCRs Heterodimers’ Interfaces
por: Nchourupouo, Karim Widad Temgbet, et al.
Publicado: (2023)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
por: Baker, Andrew T., et al.
Publicado: (2014)

EGFR Expression in HER2-Driven Breast Cancer Cells
por: Weinberg, Florian, et al.
Publicado: (2020)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2(+) Breast Cancer
por: Yu, Xiaolin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_441ttkb78hn2kqem9tqjmu42o8